Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-13
2005-12-13
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C530S328000
Reexamination Certificate
active
06974791
ABSTRACT:
Peptide motifs which define specificity of tumor-derived endothelial cells. These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium. The specific molecular peptide motifs will facilitate diverse therapeutic and diagnostic applications including: anti-angiogenic therapies to be used in alone or in conjunction with standard therapies; imaging tools for both detection of very small metastasis that are undetectable by current techniques; for monitoring tumor response; for targeting and directing chemotherapy drugs to the tumor; for treatment of chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, for treating some forms of blindness; as well as other diagnostic and therapeutic applications.
REFERENCES:
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6022541 (2000-02-01), Senger et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6348350 (2002-02-01), Goddrd et al.
patent: 6350450 (2002-02-01), Godowski et al.
patent: WO 90/03801 (1990-04-01), None
patent: WO 00/04052 (2000-01-01), None
patent: WO 00/23476 (2000-01-01), None
patent: WO 01/62930 (2001-08-01), None
Abstract of Peters et al (British journal of Cancer, 1998, vol. 77, pp. 51-56).
Alberts et al (Molecular Biology of the Cell, 1989, pp. 962-963.
Accession No. AAM49503, 1998.
Accession No. AAU77264, 1998.
Accession No. AAO20102, 1999.
Accession No. AAO14302, 1999.
Accession No. AAU78102, 1999.
Accession No. AAE19825, 2002.
Accession No. AAE20195, 2002.
Ellerby, H. M. et al.; Anti-Cancer Activity of Targeted Pro-Apoptotic Peptides; Nature Medicine, vol. 5, No. 9, pp. 1032-1038; 1999.
Ghose et al., Preparation of antibody-linked cytotoxic agents. Methods Enzymol. 93: 280-333, 1983.
Ghose et al., The design of cytotoxic-agent-antibody conjugates. Crit. Rev. Ther. Drug. Carrier Syst. 3(4):263-359. 1987.
Pierschbacher M.D. and Ruoslahti E. The cell attachment activity of fibronectin can be duplicated by small fragments of the molecule. Nature 1984; 309:30.
Koivunen E, Gay D, Ruoslahti E. Selection of peptides binding to the α5β1integrin from phage display library. J Biol Chem 1993; 268: 20205.
Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the α5β1integrin from a phage display library. J Cell Biol 1994; 124:373.
Healy JM, Murayama O, Maeda T, et al. Peptide ligands for integrin α5β3selected from random phage display libraries. Biochemistry 1995; 34:3948.
Pasqualini R, Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380:364.
Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102:430.
Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Ca Res 2000; 60:722.
Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315.
Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249:386.
Clackson T, Wells JA. In vitro selection from protein and peptide libraries. Trends Biothechnol 1994; 12:173.
Colas P, Cohen B, Jessen T, et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 1996; 380:548.
Lu Z, Murray KS, van Cleave V, et al. Expression of thioredoxin random peptide libraries onEscherichia coli(E. coli) cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Bio/Technology (NU) 1995; 13:366.
Baatout S. Endothelial differentiation using Matrigel (Review). Anticancer Res 1997; 17:451.
Zhu D, Pauli BU. Generation of monoclonal antibodies directed against organ-specific endothelial cell surface determinants. J Histochem Cytochem 1991; 39:1137.
Pierschbacher MD, Ruoslahti E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci USA 1984; 81:5985.
Yamada KM, Kennedy DW. Dualistic nature of adhesive protein function: fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. J Cell Biol 1984; 99:29.
Gartner TK, Bennett JS. The tetrapeptide analog of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985; 260:11891.
Plow EF, Pierschbacher MD, Ruoslahti E, et al. The effect of Arg-Gly-Asp containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82:8057.
Brown CK, Modzelewski RA, Johnson CS, and Wong MKK. A novel approach for the identification of unique tumor vasculature binding peptides using anE. colipeptide display library. Ann. Of Surg. Onc. 2000; 7(10): 743-749.
Suzuki S, Oldberg A, Hayman EG, et al. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4:2519.
Gardner JM, Hynes RO. Interaction of fibronectin with its receptor on platelets. Cell 1985; 42:439.
Ito Y, Iwamoto Y, Tanaka K, et al. A quantitative assay using basement membrane extracts to study tumor angiogenesis in vivo. Int J Cancer 1996; 67:148.
Modzelewski RA, Davies P, Watkins SC, Auerback R, Chang M-J, Johnson CS. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Ca Res 1994, 54:336-339.
Brown Charles Komen
Johnson Candace S.
Modzelewski Ruth A.
Trump Donald L.
Wong Michael K.
Canella Karen A.
Reed Smith LLP
The University of Pittsburgh
LandOfFree
Endothelial specific targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endothelial specific targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelial specific targeting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3499546